Last reviewed · How we verify

AD 237 — Competitive Intelligence Brief

AD 237 (AD 237) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine A2A receptor antagonist. Area: Oncology.

phase 2 Adenosine A2A receptor antagonist Adenosine A2A receptor (A2AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AD 237 (AD 237) — Sosei. AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AD 237 TARGET AD 237 Sosei phase 2 Adenosine A2A receptor antagonist Adenosine A2A receptor (A2AR)
AD109 AD109 Apnimed phase 3 Adenosine A2A receptor antagonist Adenosine A2A receptor
Istradefylline (KW-6002) Istradefylline (KW-6002) Kyowa Kirin, Inc. phase 3 Adenosine A2A receptor antagonist Adenosine A2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine A2A receptor antagonist class)

  1. Apnimed · 1 drug in this class
  2. Kyowa Kirin, Inc. · 1 drug in this class
  3. Sosei · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AD 237 — Competitive Intelligence Brief. https://druglandscape.com/ci/ad-237. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: